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1. Introduction  
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease that is intractable to currently 
available treatment modalities (Vincent et al. 2011). Failure of standard chemo-, radio- and 
neoadjuvant single pathway targeted therapies indicate that before newer treatment 
regimens are designed, one has to re-visit the basic understanding of the origins and 
complexity of PDAC. As such, PDAC is now appreciated to have not only a highly 
heterogeneous pathology but is also a disease characterized by dysregulation of multiple 
pathways governing fundamental cell processes (Kim and Simeone 2011). Such 
complexity has been suggested to be governed by molecular networks that execute 
metabolic or cytoskeletal processes, or their regulation by complex signal transduction 
originating from diverse genetic mutations (Figure 1). A major challenge, therefore, is to 
understand how to develop actionable modulation of this multivariate dysregulation, 
with respect to both how it arises from diverse genetic mutations and to how it may be 
ameliorated by prospective treatments in PDAC. Lack of understanding in both these 
areas is certainly a major underlying reason for failure of most of the available and 
clinically used drugs (Stathis and Moore 2010). The pharmaceutical industry handpicked 
drugs have been generally based on their specificity towards a particular protein and the 
subsequent targeted pathway (K-Ras, PI3K, MEK, EGFR, p53 etc) without considering the 
effect of modulating secondary and interacting pathways (Almhanna and Philip 2011; 
Philip 2011). However, as results from integrated network modeling and systems biology 
studies indicate, targeting one protein is not straightforward as each protein in a cellular 
system works in a complex interacting network comprised of a myriad interconnected 
pathways (Wist et al. 2009a). Silencing one protein/pathway can have multiple effects on 
different secondary pathways leading to secondary effects. For example, activation of 
salvage pathways (commonly observed in PDAC) can result in diminished drug response 
or in some cases acquired resistance. Therefore, in order to decode this complexity and to 
understand both the PDAC disease and identify drug targets, it requires a departure from 
a protein-centric to a more advanced network-centric view. This chapter deals with recent 
advancements on deciphering PDAC disease networks and drug response networks based 
on integrated systems and network biology-driven science. It is believed that such 
integrated and holistic approach will help in not only delineating the mechanism of 
resistance of this complex disease, it will also aid in the future design of targeted drug 
combinations that will improve the dismal cure rate.  
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Fig. 1. Genetic alterations in PDAC are categorized into early state (oncogenes, K-Ras, 
Her2/Neu); Late Stage (tumor suppressors, p16, Smad4, BRCA2) and chromosomal 
instability pathways that accelerate progression from PanIN-1A lesions to metastatic PDAC. 
2. Complex PDAC genetic network 
PDAC is highly complex malignancy with myriad set of de-regulated mechanisms involved 
and affecting the tissue at different stages of the disease. Detailed molecular mechanisms of 
initiation, development and progression of PDAC have been thoroughly studied since the 
basic principles of the disease were revealed in the 1970s (Pour et al. 2003; Morosco et al. 
1981; Morosco and Goeringer 1980). The most acceptable model is the classical one that 
describes morphological as well as molecular transformation from precursor lesions into 
invasive carcinoma (Hruban et al. 2000a; Hruban et al. 2000b). While the standard 
nomenclature and diagnostic criteria for classification of PDAC has primarily been based on 
grades of pancreatic intraepithelial neoplasia (PanIN) (Hruban et al. 2001), cumulatively it 
has been accepted that PDAC is a genetically and epigenetically complex disease that arises 
through a combination of events. It is increasingly being accepted that these complexities 
cannot be fully understood by traditional molecular biology techniques and integrated 
approaches may play pivotal role in the better understanding of PDAC as are discussed 
below.  
2.1 Interaction of oncogenes and tumor suppressor genes in PDAC  
PDAC origin and progression is broadly classified to be result of three major events (a) early 
stage genetic alterations in the proto-oncogenes mainly K-ras and Her-2/Neu; (b) late stage 
alterations in tumor suppressor genes such as p53, p16, Smad4 and BRCA2 and (c) 
chromosomal instability/precursor lesion in the normal duct (i.e. formation of PanIN-1a and 
PanIN-1B to Pan-IN-2 and Pan-IN3 (summarized in Figure 1).  
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These early and late genetic alterations have fundamental roles affecting key guardians of 
cellular signaling, which induces instability of entire molecular systems such as cell growth, 
division, apoptosis and migration. Mutation in proto-oncogenes gives rise to oncogenes that 
are often present in PDAC. These mutations cause the protein products of oncogenes to be 
permanently activated, resulting in uncontrolled cell proliferation. Oncogenic mutations 
exhibit a dominant characteristic and deficiency of one allele (i.e. heterozygous mutation) is 
sufficient for a lethal outcome. There are several key proto-oncogenes involved in PDAC, 
including KRAS, Her2/Neu, CTNNB1 (β-catenin), PIK3CA or AKT1. The most common 
oncogenic mutation types are point mutations, deletions, gene amplifications, and gene re-
arrangements. 
On the other hand, tumor suppressor genes code for proteins that act against cell 
proliferation. As a result of late event genetic alterations, their normal function may be 
reduced or even completely eliminated. Mutations in tumor suppressor genes have 
recessive characteristics and hence, the cell looses its function only when both alleles are 
affected. Commonly, described as a double hit model, one allele is initially mutated while 
the other is subsequently mutated or lost completely (Serra et al. 1997). In addition, there are 
numerous epigenetic controls of tumor suppressors that involve deactivation by 
hypermethylation (Herman et al. 1996). In PDAC, the frequently affected tumor suppressors 
include the guardian regulator TP53 (Barton et al. 1991), APC (Horii et al. 1992); SMAD4 
(Bartsch et al. 1999) and TP16 (Caldas et al. 1994).  
2.1.1 Complex de-regulatory signaling mechanisms in PDAC 
Intense research over the last three decades have revealed that PDAC has a highly intricate 
web of de-regulatory signaling. In pancreatic duct cells, molecular biologist have identified 
some of the core signaling pathways that are aberrantly expressed that consequently leads 
to development of PDAC. Major cell surface receptor de-regulatory mechanisms include the 
c-MET/HGF (hepatocyte growth factor) signaling pathway which is a key factor in early 
progression of PDAC. This pathway is responsible for invasive growth of PDAC through 
activation of key oncogenes, angiogenesis and scattering (cell dissociation and metastasis). c-
MET is a proto-oncogene that encodes an HGF receptor that has a primary function in 
embryonic development and wound healing (Chmielowiec et al. 2007). Even though c-MET 
mRNA is present at very small amounts in normal human exocrine pancreas, it is 
upregulated in a majority of PDAC. Interestingly overexpression of c-MET has been 
observed in regenerative tissue affected by acute pancreatitis (Otte et al. 2000), and has been 
linked to early events in PDAC carcinogenesis. HGF is a primary ligand of c-MET. Upon c-
MET/HGF interaction, several different signaling pathways are activated, including the Ras, 
phosphoinositide 3-kinase (PI3K), JAK signal transducer and activator of transcription 
(STAT) and β-catenin (Wnt) pathways.  
The second major cell surface signaling found altered in PDAC is the Ras/Raf/MAPK 
pathway. The Ras/Raf/mitogen-activated protein kinase (MAPK) pathway is one of the 
most elaborately studied signaling pathways in PDAC and other cancers (Molina and Adjei 
2006). The role of Ras/Raf/MAPK signaling is critical for many carcinogeneic processes, 
including cell growth, division, cell differentiation, invasion and migration, wound healing 
repair, and angiogenic processes. The central regulator of this multivariate signal 
transduction from extracellular to intracellular environment is the Ras protein, which is 
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localized at the inner side of the cellular membrane. Under normal physiological conditions, 
the hydrophobic Ras protein is in its inactive GDP-bound form. In the event of an 
extracellular signal coming through growth factor receptors, their is removal of GDP from 
Ras protein and its subsequent activation upon binding to GTP. Activated Ras complex 
triggers kinase activity of Raf kinase, which ultimately results in activation of an MAPK. 
MAPK kinase (MAPKK) in turn is an important regulator of DNA transcription and mRNA 
translation. Mutations that affect any of the Ras/Raf/MAPK members produce an increase 
in tumorigenicity through hyper-activation of DNA machinery and mRNA translation. 
Besides Raf and MAPK, there are other downstream effectors of Ras protein, including 
PI3K, thus providing crosstalk between multiple pathways. 
Aside from Ras pathway, the PTEN/PI3K/AKT signaling axis is found altered in PDAC. 
This pathway is fundamentally based on regulated activation of AKT through its 
localization at the cell membrane (Carnero et al. 2008). PI3K and PTEN phosphatases are 
two important protein families involved in the membrane localization of AKT. PI3K 
phosphorylates certain membrane-bound lipids known as phosphoinositides producing 
three different phosphatidylinositol 3-phosphate (PIP), phosphatidylinositol (3,4)-
bisphosphate (PIP2), and phosphatidylinositol (3,4,5)-trisphosphate (PIP3). The 
phosphorylated forms, PIP3 and, to a lesser extent, PIP2, attract important protein kinases to 
the cell membrane. The most prominent is AKT, a family of serine/threonine protein 
kinases that trigger a number of key cellular processes, including glucose metabolism, cell 
proliferation, and apoptosis, transcription, and cell migration (Maitra and Hruban 2005). 
AKT activity is strongly dependent on its proper localization on the cell membrane. The 
positioning of AKT at the membrane is achieved through its strong binding to PIP3. In 
pancreatic carcinogenesis, AKT1 acts as an oncogene that upholds cell survival by 
overcoming cell cycle arrest, blocking apoptosis, and promoting angiogenesis. PTEN is a 
phosphatase that acts in opposition to PI3K. It has tumor suppression ability by 
converting PIP3 back to PIP2 and to PIP, hence disrupting membrane localization and 
reducing activity of AKT. In most cancers, expression levels of PI3Ks and AKT are high, 
while PTEN is often deactivated by mutation, or deleted completely. Through its key role 
in pancreatic carcinogenesis, PI3K/AKT/PTEN signaling is an important target for 
anticancer therapy. 
The JAK/STAT signaling pathway also has an important role in regulation of DNA 
transcription by inducing chemical signals from cytokine receptors into the cell nucleus. The 
signal is phosphorylation dependent prompting activation and dimerization in a family of 
STAT proteins. Activated STAT dimers initiate DNA transcription inside the nucleus. It is 
known that inhibition of JAK/STAT signaling induces apoptosis in various human cancers, 
and is therefore, a primary focus for potential new drug candidates (Buettner et al. 2002). A 
recent study has reported reduced growth of pancreatic cancer cells in vitro when exposed to 
benzyl isothiocyanate, through suppression of STAT3 signaling and subsequent induction of 
apoptosis. This is suggested as a possible explanation of the anti-carcinogenic effect of 
cruciferous vegetables (such as broccoli, cauliflower, cabbage or horseradish) that are rich in 
isothiocyanates. 
TGF-β is a ligand that binds to type II cytokine receptor dimer, which then interacts and 
activates type I cytokine receptor dimer, triggering phosphorylation of receptor-regulated 
SMADs (R-SMADs), mainly SMAD2 and SMAD3. In the phosphorylated form, the R-
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SMADs form a complex with SMAD4, which localizes it in the nucleus and where it 
interacts with other factors to stimulate transcription of genes that are important for cell 
cycle arrest and migration. SMAD4 is therefore a key mediator for TGF-β signals. Due to its 
frequent absence in proliferating PDAC tissue, it is also known as DPC or “deleted in 
pancreatic cancer” (Schutte et al. 1995). Relatively high frequency of SMAD4 mutations and 
loss of heterozygosity at the DPC4 locus (18q21.1) strongly suggest that the protein is a 
primary tumor suppressor involved in PDAC carcinogenesis process. However, it should be 
noted that reinstating SMAD4 expression results in tumor growth suppression only in vivo 
and not in vitro. It has also been found that a SMAD4-independent pathways may be 
responsible for tumorigenic effect of TGF-β signaling (Levy and Hill 2005). 
Wnt signaling is crucial to formation and maintenance of pancreas (Dessimoz and Grapin-
Botton 2006; Dessimoz et al. 2005). During PDAC development, hyper-activation of Wnt 
triggers transcription of a number of genes that have a direct impact on cell proliferation, 
differentiation and migration (Cano et al. 2008; Rulifson et al. 2007). Activation of Wnt 
signaling is through interaction of a family of membrane-bound receptors known as 
Frizzleds with Wnt ligands. Once activated, the downstream signals may proceed through 
independent pathways. In a canonical pathway, signal transduction is mediated through 
stabilization and translocation of β-catenin from the cytosol into the nucleus followed by its 
interaction with T-cell factor that in turn activates transcription of target genes. The 
localization of high expression levels of β-catenin in the nucleus has been experimentally 
confirmed in various high grade PanIN lesions, as well as in advanced PDAC (Al-Aynati et 
al. 2004). In non-canonical, β-catenin-independent pathways, other signaling mediators are 
involved, that block the β-catenin assisted transcription. The nuclear localization of β-
catenin and high expression levels of WNT5a, a gene involved in non-canonical Wnt 
pathways, suggests involvement of both pathways in PDAC progression. 
The cell cycle control genes have profound importance in PDAC and CDKN2A is one of key 
factors in its negative control. The CDKN2A has two promoters and alternative splicing sites 
that give rise to two alternative protein products: cyclin-dependent kinase inhibitor 
p16INK4a and p53-activator p14ARF. Although both proteins are active in negative control 
of the cell cycle, only the function of p16INK4a is frequently lost in PDAC due to point 
mutations, deletions or hypermethylation . p16INK4a protein (also known as p16) inhibits 
key elements of cell cycle progression at the G1 checkpoint. p16 inactivation is an early 
event in pancreatic carcinogenesis, and low levels of p16 expression are associated with 
larger tumors, risk of early metastases and poor survival. The network interactions of de-
regulatory signaling pathways in PDAC are depicted in Figure 2.  
In summary, the above comprehensive set of studies accumulated over the years clearly 
show that PDAC is a highly complex disease. Traditional molecular biology focuses on 
studying these alterations in a single protein-centric manner honing on individual 
pathways. There are unanswered questions regarding the interaction between these de-
regulatory signaling mechanisms that may be related to the cause of such dismal outcomes 
in PDAC. This is indeed the case as pharmaceutical companies handpick drugs to target 
individual protein and not multiple pathways. Even if a drug blocks one signaling molecule 
in the tumor, another salvage pathway becomes activated leading to diminished efficacy of 
the drugs. Therefore, we are of the view that an integrated holistic approach is needed to to 
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first understand the interactions between individual pathways that will aid in the design of 
single or combination regimens for the elimination of PDAC.   
 
  
 
Fig. 2. Complex de-regulatory network of PDAC obtained from Ingenuity Pathway Analysis 
Database.  
3. Systems biology and its use in understanding the complexity of PDAC 
Applicability of systems biology is slowly being realized in the clinic (Faratian et al. 2009). 
Currently, combining information on patient history with high throughput bioinformatics 
such as genotyping, transcriptomics and comparative genomic hybridization, sequencing, 
and proteomics, followed by molecular network analysis, one can predict biomarkers and 
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targets and that would ultimately benefit in designing personalized medicine (Figure 3 
depicting integration of multiple high-throughput technologies for better approach and 
treatment to a disease). 
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Fig. 3. Systems Biology is a potent tool for designing personalized medicine, predicting 
biomarkers and targets and mechanistic understanding of complex diseases.  
This type of association study can be applied to both affected and healthy cohorts, or in 
relation to particular phenotypes, such as disease susceptibility (for example, diabetes) 
(Saxena et al. 2007), or to study individual responses to drugs. As a result, genetic variations 
have been identified through comprehensive re-sequencing studies of cancer-related 
mutations in colon and breast tumors, leading to the identification of around 80 DNA 
alterations in a typical cancer (Wood et al. 2007). This technology has been applied to 
understand PDAC genetics, pathway interactions and in identifying PDAC stem cells and 
are discussed below. 
3.1 Systems understanding of PDAC expression datasets 
As a proof of concept, the first study on the use of proteomic profiling was published by 
Lohr and group and they showed how integrated technologies could be utilized in 
obtaining PDAC biomarkers (Lohr et al. 2006). In this study, it was postulated that this type 
of proteomic approach was extremely necessary in the rationale for the design of drugs for 
this deadly malignancy. Later, a number of investigations have demonstrated that indeed 
this technology can be applied to unwind the complex web of interacting pathways in 
PDAC. For example, in an elegant study, Chelala and colleagues provided pancreatic 
expression database that was a generic model for organization, integration and mining of 
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complex pancreatic cancer datasets (Chelala et al. 2007). The database holds 32 datasets 
comprising 7636 gene expression measurements extracted from 20 different published gene 
or protein expression studies from various PDAC types, pancreatic precursor lesions 
(PanINs) and chronic pancreatitis. The pancreatic data are stored in a data management 
system based on the BioMart technology alongside the human genome gene and protein 
annotations, sequence, homologue, SNP and antibody data. Interrogation of the database 
can be achieved through both a web-based query interface and through web services using 
combined criteria from pancreatic (disease stages, regulation, differential expression, 
expression, platform technology, publication) and/or public data (antibodies, genomic 
region, gene-related accessions, ontology, expression patterns, multi-species comparisons, 
protein data, SNPs). This database enables connections between otherwise disparate data 
sources and allows relatively simple navigation between all data types and annotations. The 
database structure and content provides a powerful and high-speed data-mining tool for 
cancer research. It can be used for target discovery i.e. of biomarkers from body fluids, 
identification and analysis of genes associated with the progression of cancer, cross-platform 
meta-analysis, SNP selection for pancreatic cancer association studies,  
cancer gene promoter analysis as well as mining cancer ontology information. The  
data model is generic and can be easily extended and applied to other types of cancer and is  
available online with no restrictions for the scientific community at 
http://www.pancreasexpression.org/. Building on this database, the same group has 
updated their PDAC expression studies combining newly discovered and emerging 
molecules in 2011 (Cutts et al. 2011). These studies were not possible through traditional 
molecular biology approach which has its own limitations. In addition to the 32 datasets 
discovery, the group has added newer, more sophisticated query types that serve as a 
prototype for possible questions of interest that might be addressed towards greater 
understanding of PDAC (Chelala et al. 2009). 
3.1.1 Integrated systems biology in identification of PDAC biomarkers 
Comprehensive progress has been made on the use of systems biology in identification of 
biomarkers for PDAC. In a recent study, PDAC cell line related conditioned media and 
pancreatic juice were both mined for identification of putative diagnostic leads (Makawita et 
al. 2011). The proteome of the condition media were identified using strong cation exchange 
chromatography, followed by LC-MS/MS on an LTQ-Orbitrap mass spectrometer from six 
pancreatic cancer cell lines (BxPc3, MIA-PaCa2, PANC1, CAPAN1, CFPAC1 and SU.86.86), 
one normal human pancreatic ductal epithelial cell line, HPDE, and two pools of six 
pancreatic juice samples from ductal adenocarcinoma patients. These studies identified 1261 
and 2171 proteins with two or more peptides, in each of the cell lines, while an average of 
521 proteins were identified in the pancreatic juice pools. In total, 3,479 non-redundant 
proteins were identified with high confidence, of which ~40% were extracellular or cell 
membrane-bound based on genome ontology classifications. Three strategies were 
employed for identification of candidate biomarkers (1) examination of differential protein 
expression between the cancer and normal cell lines using label-free protein quantification, 
(2) integrative analysis, focusing on the overlap of proteins between the multiple biological 
fluids, and (3) tissue specificity analysis through mining of publically available databases. 
However, further validation of these proteins is warranted, as is the investigation of the 
remaining group of candidate biomarkers in PDAC. In another study on PDAC, secreted 
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serum biomarker identification the profiling pancreatic cancer-secreted proteome using 15N 
amino acids and serum-free media was performed (Xiao et al. 2010). In this study the effect 
of oxythiamine chloride on PDAC cell secreteome was studied. The authors further 
improved on the existing biomarker discovery technology (i.e. coupling of proteomics and 
in vitro labeling of proteins in cells (SILAC) to enhance the efficacy of biomarker discovery. 
The authors concluded that labeling protein with 15N amino acids in conjunction with 
depleted serum allows the identification of actively secreted proteins from pancreatic cancer 
cells, and the rate of production of a secreted protein may be used as an independent 
biomarker of the presence of tumor. 
3.1.2 Integrated analysis of pathways collectively targeted by co-expressed 
microRNAs in PDAC 
Apart from investigations on signaling pathway de-regulation, multiple recent studies have 
found aberrant expression profiles of small non-coding RNAs (microRNAs) in PDAC. While 
several target genes have been experimentally identified for some microRNAs in various 
tumors, the global pattern of cellular functions and pathways affected by co-expressed 
microRNAs in PDAC remained elusive. Here too systems biology has found application in 
identification through computational approach and global analysis of the major biological 
processes and signaling pathways that are most likely to be affected collectively by co-
expressed microRNAs in cancer cells. In a recent study, using five datasets of aberrantly 
expressed microRNAs in pancreatic and other cancers (breast cancer, colon cancer, lung 
cancer and lymphoma) and combinatorial target prediction algorithm miRgate and a two-
step data reduction procedure Gene Ontology categories were determined (Gusev 2008; 
Gusev et al. 2007). These studies demonstrated biological functions, disease categories, 
toxicological categories and signaling pathways that are: targeted by multiple microRNAs; 
statistically significantly enriched with target genes; and known to be affected in PDAC. The 
analysis of predicted miRNA targets suggests that co-expressed miRNAs collectively 
provide systemic compensatory response to the abnormal phenotypic changes in cancer 
cells by targeting a broad range of functional categories and signaling pathways known to 
be affected in PDAC. The analysis revealed that E2F1 is a predicted microRNA target as well 
as caspase3 that were also validated experimentally as a target of multiple miRNAs in 
PDAC. Such a systems biology based approach provides new avenues for biological 
interpretation of miRNA profiling data and generation of experimentally testable 
hypotheses regarding collective regulatory functions of miRNA in PDAC for the design of 
effective therapies. 
3.1.3 Proteomic profiling in identification of PDAC stems cells 
PDAC tumors are heterogenous in nature and harbor many different types of cells. In recent 
years it has been realized that PDAC and other tumors carry a sub-population of cells with 
stem cell characteristics that are resistant to chemotherapeutic treatment modalities. 
However, this concept is still controversial since these cells have yet to be comprehensively 
identified and characterized. PDAC stem cells (CSCs) are such a group of cells that only 
constitute 0.2-0.8% of the total tumor cells but have been found to be the origin of 
carcinogenesis and metastasis. However, the extremely low availability of pancreatic tissue 
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CSCs (around 10 000 cells per xenograft tumor or patient sample) has limited the utilization 
of currently available molecular biology techniques. Global proteome profiling of pancreatic 
CSCs from xenograft tumors in mice using integrated systems biology is a promising way to 
unveil the molecular machinery underlying the signaling pathways in these CSCs. Using a 
capillary scale shotgun technique by coupling offline capillary isoelectric focusing (cIEF) 
with nano reversed phase liquid chromatography (RPLC) followed by spectral counting 
peptide quantification, Lubman and group investigated the proteomic profile of PDAC 
stems cells (Dai et al. 2010). In comparison with a non-tumorigenic tumor cell sample, 
among 1159 distinct proteins identified with FDR and less than 0.2%, 169 differentially 
expressed proteins are identified after multiple testing corrections where 24% of the proteins 
are up-regulated in the CSCs group. Ingenuity Pathway analysis of these differential 
expression signatures further indicated that a significant involvement of signaling pathways 
related to cell proliferation, inflammation, and metastasis were indentified. This was the first 
study to represents the proteome profiling study on PDAC stem cells from xenografted 
tumors in mice. 
4. Systems biology can aid understanding of the drug mechanism of action 
in PDAC 
Although partially successful in PDAC, new adjuvant targeted therapies (k-ras, EGFR, 
VEGF, src etc) have been met with more failure than success. The major reason for the low 
response is related to incomplete understanding and validation of the specific molecular 
targets at the gene level. The complexities of genetic and epigenetic changes in PDAC, 
coupled with redundancies and cross-talk in signaling pathways may explain the failure of 
single-pathway targeted therapies. This can be envisioned from the fact that of the 25,000 
genes representing the human genome, about 1,800 are involved in the etiology of 
numerous diseases including cancer (Wist et al. 2009b). Currently available FDA approved 
drugs (~ 1200 in the market) have been designed to target approximately 400 genes 
(Drugome). However, targeting this drugome by individually analyzing each gene is an 
impossible task because the functional product of each gene or (Proteome) is under multiple 
control, including splice variants and post translational modifications, giving rise to >40,000 
functionally distinct proteins. In addition, such studies, thus far have been hindered by lack 
of suitable rapid technology. Therefore, novel and high-throughput data acquisition 
technologies coupled with integrated systems network modeling are urgently required to 
identify target genes in a tumor-specific manner. Such technologies are crucial for 
identifying and understanding the mechanisms of potential target candidates in complex 
diseases like PDAC.  
4.1 Systems pharmacology view of drug action  
Most of the known targeted drugs currently being used in the clinic were initially designed 
to affect a single gene. Unfortunately, contrary to the original idea, even the most specific 
drugs eventually target more than one gene (in most cases, >10 secondary targets). The use 
of systems pharmacology categorizes these off-targets into two types i) off-targets (resulting 
in side effects [often toxic]) and ii) secondary targets resulting in partial synergy] (Figure 4) 
(Berger and Iyengar 2009). These secondary targets exist within a complex network which 
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can mediate the response to the drugs leading to both therapeutic and adverse effects. 
Understanding these beneficial secondary targets specially observed in potent synergistic  
combinations will provide fundamental information for the design of the most potent drug  
combination for individualized/personalized treatments.   
 
 
 
 
 
 
Fig. 4. Traditional vs Network view of drug mechanism of action. Network view differs in 
understanding the mechanism of action of drugs. Classic view pools all secondary effects as 
off targets that are considered to cause side effects and toxicity. Network pharmacology 
categorizes secondary targets into off targets and interacting secondary targets which can 
mediate the response to the drugs to both the therapeutic or adverse effects. Adopted from 
Azmi et al., 2011b 
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Such an understanding requires mechanistic studies in the laboratory to be coupled with 
robust, state of the art computational tools to obtain irrevocably strong proof for the 
integration of pathways involved in the observed synergy. One such approach involves the 
use of network modeling which provides mathematically and statistically robust 
information regarding the involvement of effector genes in the efficacy or synergy between 
two drugs. These network models can also predict key secondary targets of such interaction, 
thus, also providing information on novel previously unrecognized targets and pathways 
which could be useful for future therapeutic interventions in the treatment of different 
cancers where, at present, information is gravely lacking, such as in PDAC. 
4.1.1 Validation of the systems approach for predicting potent drug combination in 
PDAC  
Our laboratory has been working on a specific small molecule inhibitor of MDM2 (MI-
219) and indentifying, in greater detail, its mechanism of action in PDAC (Azmi et al. 
2010b). MI-219 is currently in Phase I clinical trial (Brown et al. 2009). Our initial studies 
were restricted to evaluating its efficacy against wt-p53 tumors. However, we have 
recently found that MDM2 inhibitor, when combined with chemotherapy such as 
oxaliplatin, synergistically enhanced apoptosis in wt-p53 cancers and most importantly, 
50% of tumor bearing mice treated with this combination remained tumor free without 
recurrence for 120 days (Azmi et al. 2010a). We used this model to validate a systems 
approach in predicting potent drug combinations in PDAC and to obtain critical 
information into understanding the mechanism for this synergy. Therefore, our study 
included integrated microarray gene expression profiling (IGEMP) and pathway network 
modeling (PNM) (Azmi et al. 2011a). The systems analysis data for MI-219-oxaliplatin 
combination treated wt-p53 capan-2 cells revealed that indeed synergy is at the gene level. 
Principle component analysis showed that one can differentiate the gene signatures 
between single treatment versus combination. The emergence of certain unique synergy-
related genes indicated their potential as key players supporting the overall response of 
MI-219-oxaliplatin in positively regulating the p53 re-activation (Azmi et al. 2010c; Azmi 
et al. 2011b). Presented with this vast amount of information regarding the mechanism 
involved in the response to MI-219-oxaliplatin synergy, we believe it validates the 
applicability of this technology for use in identifying the relevant pathways involved in 
both cure and resistance. Ultimately, results of these studies will significantly aid in the 
design of clinically successful drug combinations for PDAC, which will benefit the overall 
survival of patients.  
4.1.2 Systems identification of biomarker of response with implications for PDAC 
therapy 
Our intended goal in using IGEMP and PNM analysis was to demonstrate the synergy 
between MI-219-oxaliplatin at the gene level and to demonstrate the local network of p53 
and crucial neighboring network that augment p53 re-activation mediated events. Systems 
network modeling, although a powerful technological tool has not yet been fully explored 
for use in PDAC (the most genetically complex cancer). We had previously identified 
several genes responsible for cross-talk within the local network of p53 which included NF-
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kB, cadherin anti-tumor module, the tumor suppressor EGR1 and MDM2 negative regulator 
CREBBP. Our more in-depth analysis using these integrated approach, revealed the 
prominent role of HNF4A (hepatocyte nuclear factor 4 alpha) that modulates a totally 
distinct yet p53-linked set of proteins driving apoptosis (Azmi et al. 2010c). The 
identification of HNF4A as a key player was certainly revealing since it has not been well 
defined in PDAC cells used in this study (Capan-2 (wt-p53)). However, a search of the 
literature indicated that this gene is highly expresses in pancreatic tumors compared to their 
normal counterpart. HNF4A is known to interact with the p53 positive regulator CREBBP 
(Yoshida et al. 1997) and thus, confirmed its role in augmenting apoptotic effects in this 
synergic combination. Therefore, not only does systems biology provide information on the 
networks involved in drug efficacy, it can also provide information on biomarkers of 
therapeutic response that can be utilized for evaluation of drug response during actual 
clinical trials in PDAC patients.  
5. Conclusion  
PDAC is a complex disease that arises from a complex set of genetic mutations and 
pathway alterations. Traditional sciences have not been very successful in clearly 
delineating the interaction between these multiple pathways and this could be the 
primary reason for the observed failure of chemo- and targeted therapies. All of these 
genetic alterations can now be “re-discovered” using next-generation integrated systems 
technology. As described above, integrated sciences have revealed that these signaling 
pathways cross talk with one another and can regulate cell growth, proliferation, survival, 
angiogenesis and metastasis in PDAC. In addition, these high-throughput technologies 
can achieve many different goals such as cataloging the driver mutations, exploring 
functional role of cancer genes, proteins and interaction networks, identifying 
microRNAs, understanding protein–DNA interactions, and comprehensive analyses of 
transcriptomes and interactomes. Furthermore, these technologies can be utilized to 
identify, understand and differentiate sub population of CSCs in PDAC heterogeneous 
tumor mass. Systems biology has the power to catalog complex events leading to origin, 
progression, recurrence and resistance of PDAC and can greatly assist in understanding 
how cancer genomes operate as part of the whole biological system. Now, high-quality 
clinical treatment and outcomes (death or survival) data from biobanks, and extensive 
genetics and genomics data for some PDAC and other tumors, including breast, 
colorectal, and lung are available. How all these clinical and genetics data could be 
integrated into reverse engineering-based network modeling to approach the extremely 
complex genotype–phenotype map of different tumors is currently being explored. These 
studies will pave way for the discovery of new molecular innovations, both predictive 
markers and therapies, towards personalized treatment of PDAC. Therefore systems 
biology can aid in the overall understanding of PDAC.  
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